[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Lu, K.H. and Broaddus, R.R. (2020) Endometrial Cancer. The New England Journal of Medicine, 383, 2053-2064. https://doi.org/10.1056/NEJMra1514010
|
[3]
|
赵湘铃, 段朝晖, 张敏, 等. 中国子宫内膜癌疾病负担状况及流行趋势预测[J]. 中国慢性病预防与控制, 2023, 31(8): 568-573.
|
[4]
|
Bokhman, J.V. (1983) Two Pathogenetic Types of Endometrial Carcinoma. Gynecologic Oncology, 15, 10-17. https://doi.org/10.1016/0090-8258(83)90111-7
|
[5]
|
郑文新, 沈丹华, 郭东辉, 等. 妇产科病理学(上卷) [M]. 第2版. 北京: 科学出版社, 2021: 386.
|
[6]
|
Travaglino, A., Raffone, A., Gencarelli, A., et al. (2020) TCGA Classification of Endometrial Cancer: The Place of Carcinosarcoma. Pathology & Oncology Research, 26, 2067-2073. https://doi.org/10.1007/s12253-020-00829-9
|
[7]
|
Levine, D.A. and the Cancer Genome Atlas Research Network (2013) Integrated Genomic Characterization of Endometrial Carcinoma. Nature, 497, 67-73. https://doi.org/10.1038/nature12113
|
[8]
|
Raffone, A., Travaglino, A., Mascolo, M., Carbone, L., Guida, M., Insabato, L. and Zullo, F. (2019) TCGA Molecular Groups of Endometrial Cancer: Pooled Data about Prognosis. Gynecologic Oncology, 155, 374-383. https://doi.org/10.1016/j.ygyno.2019.08.019
|
[9]
|
Talhouk, A., McConechy, M.K., Leung, S., Li-Chang, H.H., Kwon, J.S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A.N., Huntsman, D.G., Gilks, C.B. and McAlpine, J.N. (2015) A Clinicallyapplicable Molecular-Based Classification for Endometrial Cancers. British Journal of Cancer, 113, 299-310. https://doi.org/10.1038/bjc.2015.190
|
[10]
|
McAlpine, J., Leon-Castillo, A. and Bosse, T. (2018) The Rise of a Novel Classificationsystem for Endometrial Carcinoma; Integration of Molecular Subclasses. The Journal of Pathology, 244, 538-549. https://doi.org/10.1002/path.5034
|
[11]
|
吕加金, 靳双玲, 李玉凡. 子宫内膜癌分子分型的研究进展[J]. 健康研究, 2023, 43(5): 556-559.
|
[12]
|
Stelloo, E., et al. (2015) Refining Prognosis and Identifying Targetable Pathways for High-Risk Endometrial Cancer; A TransPORTEC Initiative. Modern Pathology, 28, 836-844. https://doi.org/10.1038/modpathol.2015.43
|
[13]
|
León-Castillo, A., De Boer, S.M., Powell, M.E., Mileshkin, L.R., Mackay, H.J., Leary, A., Nijman, H.W., Singh, N., Pollock, P.M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V.T.H.B.M., Edmondson, R.J., Putter, H., Kitchener, H.C., Crosbie, E.J., De Bruyn, M., Nout, R.A., Horeweg, N., Creutzberg, C.L., Bosse, T. and TransPORTEC Consortium (2020) Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy. Journal of Clinical Oncology, 38, 3388-3397. https://doi.org/10.1200/JCO.20.00549
|
[14]
|
谢玲玲, 林荣春, 林仲秋. 《2020NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(4): 333-339.
|
[15]
|
Abu-Rustum, N.R., Yashar, C.M., Bradley, K., Campos, S.M., Chino, J., Chon, H.S., Chu, C., Cohn, D., Crispens, M.A., Damast, S., Diver, E., Fisher, C.M., Frederick, P., Gaffney, D.K., George, S., Giuntoli, R., Han, E., Howitt, B., Huh, W.K., Lea, J., Mariani, A., Mutch, D., Nekhlyudov, L., Podoll, M., Remmenga, S.W., Reynolds, R.K., Salani, R., Sisodia, R., Soliman, P., Tanner, E., Ueda, S., Urban, R., Wethington, S.L., Wyse, E., Zanotti, K., McMillian, N.R. and Motter, A.D. (2021) NCCNGuidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network, 19, 888-895. https://doi.org/10.6004/jnccn.2021.0038
|
[16]
|
Walsh, C.S., Hacker, K.E., Secord, A.A., et al. (2023) Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement. Gynecologic Oncology, 168, 48-55. https://doi.org/10.1016/j.ygyno.2022.10.024
|
[17]
|
孙丽丽, 刘格丹, 贾楠, 等. 不同分子分型的子宫内膜癌临床病理特征分析[J]. 肿瘤预防与治疗, 2022, 35(5): 435-441.
|
[18]
|
Concin, N., Creutzberg, C.L., Vergote, I., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. Virchows Archiv, 478, 153-190. https://doi.org/10.1007/s00428-020-03007-z
|
[19]
|
Oaknin, A., Bosse, T.J., Creutzberg, C.L., et al. (2022) Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 860-877. https://doi.org/10.1016/j.annonc.2022.05.009
|
[20]
|
Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S.M., Chino, J., Chon, H.S., Chu, C., Crispens, M.A., Damast, S., Fisher, C.M., Frederick, P., Gaffney, D.K., Giuntoli, R., Han, E., Holmes, J., Howitt, B.E., Lea, J., Mariani, A., Mutch, D., Nagel, C., Nekhlyudov, L., Podoll, M., Salani, R., Schorge, J., Siedel, J., Sisodia, R., Soliman, P., Ueda, S., Urban, R., Wethington, S.L., Wyse, E., Zanotti, K., McMillian, N.R. and Aggarwal, S. (2023) Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21, 181-209. https://doi.org/10.6004/jnccn.2023.0006
|
[21]
|
Santoro, A., Angelico, G., Travaglino, A., et al. (2021) New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers, 13, Article 2623. https://doi.org/10.3390/cancers13112623
|
[22]
|
Karpel, H., Slomovitz, B., Coleman, R.L. and Pothuri, B. (2023) Biomarker-Driven Therapy in Endometrial Cancer. International Journal of Gynecologic Cancer, 33, 343-350. https://doi.org/10.1136/ijgc-2022-003676
|
[23]
|
Berek, J.S., Matias-Guiu, X., Creutzberg, C., et al. (2023) FIGO Staging of Endometrial Cancer: 2023. International Journal of Gynecology & Obstetrics, 162, 383-394. https://doi.org/10.1002/ijgo.14923
|
[24]
|
Jamieson, A., Barroilhet, L.M. and McAlpine, J.N. (2022) Molecular Classification in Endometrial Cancer: Opportunities for Precision Oncology in a Changing Landscape. Cancer, 128, 2853-2857. https://doi.org/10.1002/cncr.34328
|
[25]
|
Abdulfatah, E., Wakeling, E., Sakr, S., et al. (2019) Molecular Classification of Endometrial Carcinoma Applied to Endometrial Biopsy Specimens: Towards Early Personalized Patient Management. Gynecologic Oncology, 154, 467-474. https://doi.org/10.1016/j.ygyno.2019.06.012
|
[26]
|
Zakhour, M., Cohen, J.G., Gibson, A., et al. (2017) Abnormal Mismatch Repair and Other Clinicopathologic Predictors of Poor Response to Progestin Treatment in Young Women with Endometrial Complexatypical Hyperplasia and Well-Differentiated Endometrial Adenocarcinoma: A Consecutive Case Series. BJOG: An International Journal of Obstetrics & Gynaecology, 124, 1576-1583. https://doi.org/10.1111/1471-0528.14491
|
[27]
|
Chung, Y.S., Woo, H.Y., Lee, J.Y., et al. (2021) Mismatch Repair Status Influences Response to Fertility-Sparing Treatment of Endometrial Cancer. American Journal of Obstetrics and Gynecology, 224, 370.E1-370.E13. https://doi.org/10.1016/j.ajog.2020.10.003
|
[28]
|
Wang, Y., Kang, N., Li, L., et al. (2023) Characteristics of Molecular Classification in 52 Endometrial Cancer and Atypical Hyperplasia Patients Receiving Fertility-Sparing Treatment. Gynecology and Obstetrics Clinical Medicine, 3, 38-43. https://doi.org/10.1016/j.gocm.2023.01.006
|
[29]
|
Ruiz, M.P., Huang, Y., Hou, J.Y., Tergas, A.I., Burke, W.M., Ananth, C.V., Neugut, A.I., Hershman, D.L. and Wright, J.D. (2017) All-Cause Mortality in Young Women with Endometrial Cancer Receiving Progesterone Therapy. American Journal of Obstetrics and Gynecology, 217, 669.E1-669.E3. https://doi.org/10.1016/j.ajog.2017.08.007
|
[30]
|
Park, J.Y. and Nam, J.H. (2015) Progestins in the Fertility-Sparing Treatment and Retreatment of Patients with Primary and Recurrent Endometrial Cancer. Oncologist, 20, 270-278. https://doi.org/10.1634/theoncologist.2013-0445
|
[31]
|
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M.R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. International Journal of Gynecologic Cancer, 31, 12-39. https://doi.org/10.1136/ijgc-2020-002230
|
[32]
|
Alkatout, I. (2015) Kommunikative und Ethische Aspekte der Arzt-Patienten-Beziehung in der Extremsituation. Wiener Medizinische Wochenschrift, 165, 491-498. https://doi.org/10.1007/s10354-015-0385-2
|
[33]
|
De Rocco, S., Buca, D., Oronzii, L., Petrillo, M., Fanfani, F., Nappi, L., Liberati, M., D’Antonio, F., Scambia, G., Leombroni, M., et al. (2022) Reproductive and Pregnancy Outcomes of Fertility-Sparing Treatments for Early-Stage Endometrial Cancer or Atypical Hyperplasia: A Systematic Review and Meta-Analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 273, 90-97. https://doi.org/10.1016/j.ejogrb.2022.04.019
|
[34]
|
Giampaolino, P., Cafasso, V., Boccia, D., Ascione, M., Mercorio, A., Viciglione, F., Palumbo, M., Serafino, P., Buonfantino, C., De Angelis, M.C., et al. (2022) Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review. BioMed Research International, 2022, Article ID: 4070368. https://doi.org/10.1155/2022/4070368
|
[35]
|
Lehrer, S. and Rheinstein, P.H. (2021) FBXW7, L1CAM, and TGM2 in Endometrial Cancer. Cancer, 127, 4103-4104.
|
[36]
|
Emons, G., Steiner, E., Vordermark, D., et al. (2023) Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures. Geburtshilfe Frauenheilkd, 83, 919-962.
|
[37]
|
Arciuolo, D., Travaglino, A., Raffone, A., et al. (2022) TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 23, Article 11684. https://doi.org/10.3390/ijms231911684
|
[38]
|
Huvila, J., Pors, J., Thompson, E.F., et al. (2021) Endometrial Carcinoma: Molecular Subtypes, Precursors and the Role of Pathology in Early Diagnosis. The Journal of Pathology, 253, 355-365. https://doi.org/10.1002/path.5608
|
[39]
|
Mutlu, L., Harold, J., Tymon-Rosario, J., et al. (2022) Immune Checkpoint Inhibitors for Recurrent Endometrial Cancer. Expert Review of Anticancer Therapy, 22, 249-258. https://doi.org/10.1080/14737140.2022.2044311
|
[40]
|
Marabelle, A., Le, D.T., Ascierto, P.A., et al. (2020) Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair—Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 38, 1-10.
|
[41]
|
易倩琳, 蒋鹏, 朱梦秋, 等. 免疫组化标志物P53定量表达在Ⅰ~Ⅱ期子宫内膜癌中的预后价值[J]. 中国实用妇科与产科杂志, 2023, 39(5): 568-572.
|
[42]
|
刘开江. 子宫内膜癌癌症基因组图谱分子分型临床价值: 机遇, 挑战与突破[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1057-1061.
|
[43]
|
王东雁, 李晶, 林仲秋. 《子宫内膜癌分子检测: SGO临床实践声明》介绍[J]. 中国实用妇科与产科杂志, 2023, 39(2): 240-245.
|
[44]
|
刘格丹, 冯炜炜. 基于子宫内膜癌分子分型决策临床疗[J]. 中国实用妇科与产科杂志, 2022, 38(3): 378-384.
|
[45]
|
贾晴晴, 徐臻, 王利君, 等. 淋巴脉管间隙浸润对早期子宫内膜样癌预后的影响[J]. 中国实用妇科与产科杂志, 2022, 38(6): 646-649.
|